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EX viva hemoperfused pancreaticoduodenal preparations from dogs have been used to study 
intraluminal and circulatory patterns of release of immunoreactive gas&in under basal con- 
ditions and after secretin stimulation. Bidirectional release of immunoreactive gastrin was 
maximal at 3 U/min secretin infusion, and release into pancreatic and duodenal juice exceeded 
that into portal venous blood. Molecular sieving chromatography of peptides with gas&-like 
immunoreactivity recovered from duodenal and pancreatic juice indicated a single species of a 
molecular size equivalent to CCKS and smaller than minigastrin (G-14). The exact identity has 
not been defined. This study demonstrates that secretin stimulates release of gastrin-like 
peptides into blood and lumen of extra-antral gastrin-producing tissues in the dog. Uni- 
directional gastrin release patterns from gastrinoma tissue may explain the paradoxical increase 
in plasma gastrin levels in response to secretin in patients with gastrinomas (Zollinger- 
Ellison syndrome). 
INTRODUCTION 
Seventy-five years have elapsed since 
Edkins first reported that extracts of antral 
mucosa stimulated gastric acid secretion 
[6]. Gregory and Tracy are credited 
with the isolation and physicochemical char- 
acterization of gas&in in pure form [93. 
For many years gastxin was viewed as a 
hormone originating primarily from the 
gastric antrum, but precise localization of 
the site(s) of release has not been dem- 
onstrated. 
Recent observations in man and dog sug- 
gest that gastrin may be elaborated by extra- 
antral tissues [22, 331. The greatest pro- 
portion of mucosal gastrin in both species 
is localized to the gastric antrum, with 
diminishing tissue concentrations in the 
1 Address reprint requests to Frederic E. Eckhauser, 
M.D., Department of Surgery, University of Michigan 
Medical Center, 1405 E. Ann Street, Ann Arbor, 
Michigan 48109. 
small intestine from duodenum to ileum 
[33]. Although little is known about the 
ontogeny of gas&in-producing cells, they 
have been identified prenatally in man and 
rat [17, 18, 211. Gastrin release into both 
the gut lumen and the portal circulation 
has been documented, but to date there is 
equivocal evidence of “true” gastrin-pro- 
ducing cells in adult pancreas or of gastrin 
release into pancreatic juice. 
Gastrin release is mediated through com- 
plex neuroendocrine and paracrine servo- 
mechanisms. Several hormones, including 
secretin and somatostatin, are effective in 
suppressing gastrin release [7, 10, 121. 
Acidification of both the antrum and the 
duodenum has been shown to suppress the 
release of gastrin from the gastric antrum, 
presumably via different mechanisms 12, 
8, 11, 201. Secretin has been implicated 
as the major mediator of the latter servo- 
mechanism, and appears to act both by 
suppressing the release of antral gastrin 
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and by blocking the action of gastrin on 
oxyntic or parietal cells [12, 161. The 
administration of exogenous secretin nor- 
mally decreases fasting levels of immuno- 
reactive gastrin in dogs and in humans 
with “usual” forms of duodenal ulcer dis- 
ease [28]. The increase in fasting serum 
gastrin levels observed following the ad- 
ministration of secretin to patients with 
Zollinger-Ellison syndrome remains a para- 
dox [16, 281. Although the precise mecha- 
nism underlying this response is unknown, 
a direct stimulating effect of secretin upon 
gastrinoma cells has been postulated [16]. 
Recent data suggest that immunoreactive 
gastrin is released into the antral and 
duodenal lumens of cats following elec- 
trical vagal stimulation or topical applica- 
tion of acetylcholine [30]. In vitro studies 
have further shown that secretin may inhibit 
luminal release of immunoreactive gastrin 
from the antrum of the dog [7]. 
The present studies were designed to 
test the following hypotheses: first, that 
immunoreactive gastrin in the dog may be 
released from extra-antral tissues, notably 
pancreas and duodenum; second, that se- 
cretin may stimulate the release of gastrin 
from extra-antral tissues in the dog; and 
third, that bidirectional release into the 
portal circulation and lumens of pancreas 
and duodenum following secretin infusion 
may be a normal phenomenon. 
MATERIALS AND METHODS 
Specimen Preparation and Perfusion 
Technique 
Pancreaticoduodenal preparations were 
obtained from six mongrel dogs (20-25 kg 
body weight) using the technique of Ritchie 
and Hardcastle [25]. The preparation was 
maintained at normothermia and perfused 
through the superior mesenteric artery and 
one branch of the splenic artery. Venous 
effluent was collected from the portal vein. 
An 8- to lo-cm juxtapancreatic segment 
of duodenum was isolated, with preserva- 
tion of the inferior and superior pancreatico- 
duodenal veins. The ampulla of Vater was 
identified through a 3-cm duodenotomy, 
and the pancreatic duct cannulated with a 
fine metal probe. The extraduodenal portion 
of the pancreatic duct was isolated, then 
leolated Perfused Pancreas Preparation 
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FIG. 1. The anatomy of the ex viva pancreaticoduodenal preparation. 
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FIG. 2. The entire perfusion system with oxygenator/reservoir, in-line dialysis unit, and pulsatile 
perfusion pump. 
cannulated with 18.5-G medical-grade poly- 
ethylene tubing, and the proximal portion 
was ligated. Accessory pancreatic ducts 
were suture ligated when identified. Flexible 
collection tubes were secured at the proxi- 
mal and distal ends of the duodenum to 
permit perfusion of the isolated bowel 
segment and collection of specimens. The 
final preparation is illustrated in Fig. 1. 
A closed-circuit perfusion apparatus (Fig. 
2), similar to that of Vaysse and colleagues 
[3 11, was modified by the addition of an 
in-line dialysis unit (Technicon heated di- 
alyzer, Model 1). Both the perfusion cham- 
ber and the dialysis unit were primed with 
an albumin-containing perfusate solution,2 
2 Perfusate composition: Na+, 127 meqfliter; Cl-, 
105 meq/liter; HCOs-, 40 meq/liter; Ca2+, 5 meq/liter; 
K+, 3.5 meqkter; Mg2+, 2 meqihter; P04, 2 meq/ 
and the final hematocrit in the reservoir 
was adjusted to 25-30% by adding autolo- 
gous red blood cells. Blood perfusate and 
stock perfusate were withdrawn from the 
system at equal rates (28-32 ml/30 min 
through a mixing coil into the dialysis 
chamber and filtered through a Gelman 1.2- 
pm metricel membrane at a rate approxi- 
mating the intake flow. Damaged red blood 
cells and free hemoglobin were removed 
from circulation and half the blood per- 
fusate volume was replaced with fresh 
stock solution with each passage through 
the dialyzer. A rotating disk oxygenator 
liter; SO,, 1 meq/liter; bovine serum albumin (BSA), 
4 g%; glucose, 150 mg%; and mannitol to adjust the 
final osmotic pressure to 315 mosmoles/liter. One 
thousand units of aqueous heparin was added per 
liter of perfusate solution. 
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(Sarnes, Inc., Ann Arbor, Michigan), sup- 
plied with a 95% 02-5% CO, gas mixture, 
served as the blood reservoir. The prep- 
aration was perfused at a constant blood 
flow (CBF) of 20-25 mYmin using a pulsatile 
infusion pump (Harvard Products, Model 
1405). Arterial and portal pressures were 
monitored continuously and recorded (Hew- 
lett-Packard multichannel recorder, Model 
7754A). The pH, PO,, and pC0, were 
analyzed (pH blood gas analyzer, Radiom- 
eter, Copenhagen) and corrected at hourly 
intervals as needed. 
Experimental Procedure 
The duodenal segment was perfused con- 
tinuously at 2 mYmin with lactated Ringers 
solution containing phenol red indicator, 
0.6%. Addition of the dye indicator per- 
mitted rapid assessment of the luminal pH; 
change from the acid orange range signified 
contamination by alkaline pancreatic se- 
cretions. Duodenal effluent was collected on 
ice every 10 min, the volume recorded, 
and a sample obtained for subsequent gastrin 
assay. Each sample was boiled for 10 min, 
quick-frozen in a dry ice-alcohol bath, and 
stored at -20°C. Samples of dialysate were 
collected and processed in a similar fashion. 
Following a 30-min equilibration period, 
basal samples were obtained from the portal 
vein (PV), pancreatic duct (PD), and duo- 
denum (D). Trasylol (Aprotinin, Mobay 
Chemicals, New York) was added to pan- 
creatic juice at a volume ratio of 1:5 and 
the samples were quick frozen. 
Boots secretin (Boots Co. Ltd., Notting- 
ham, England) was infused at 1 U/min. 
Samples for immunoreactive gastrin assay 
were collected from portal vein, pancreatic 
duct, and duodenum at intervals of 1, 3, 5, 
10,20, and 30 min. After 30 min of infusion, 
the dose of secretin was increased to 3 U/ 
min, and after another 30 min, to 5 U/min. 
Samples were collected at the same intervals 
as above during each secretin infusion 
period and were processed rapidly and 
quick-frozen for assay at a later date. At 
the conclusion of the experiment 0.5- to 
1.0-g biopsy samples of pancreas and 
duodenum were obtained. These specimens 
were boiled in distilled water for 10 min, 
and after removing the tissue plug, the 
extract was quick-frozen. 
In order to calculate the amount of 
immunoreactive gastrin lost from the system 
by dialysis, an additional experiment was 
performed. Thirty nanograms of synthetic 
heptadecapeptide gastrin (G- 17) was added 
to a perfusion system not containing an 
organ. The final concentration of gastrin in 
the system was 100 pg/ml. Blood flow and 
reservoir volume remained constant through- 
out the procedure. Average percentage 
cumulative losses of immunoreactive gastrin 
were calculated by dividing the amount of 
gastrin measured in the dialysate per 30- 
min collection period by the total gastrin 
measured in the system (amount lost and 
that remaining) and multiplying by 100. 
Immunoreactive Gastrin Assay and 
Validation 
Immunoreactive gastrin was measured by 
a radioimmunoassay previously described 
[32]. Antiserum raised against synthetic 
human gastrin (SHG 17-I) demonstrated 1% 
cross-reactivity with CCK8 (courtesy of Dr. 
M. Ondetti, Squibb Pharmaceuticals), 0.003% 
with tetragastrin, and 0.003% with cerulean 
using 1251-gastrin 17-I as a tracer. 
Samples of juice from the duodenum and 
pancreatic duct were chromatographed on 
Sephadex G-50 superfine columns (pH 8.0; 
flow rate, 4.0 ml/m; column, 100 x 1.0 cm). 
Affinity chromatography using gastrin anti- 
serum Gz conjugated to Sepharose 4B was 
performed on samples of pancreatic and 
duodenal juice. The bound fractions were 
desorbed with 0.1 M acetic acid at pH 2.5. 
These samples were lyophillized, reconsti- 
tuted in assay buffer, and assayed for 
immunoreactive gastrin as described pre- 
viously. In a control experiment, 1251- 
gas&in 17-I was applied to the column and 
eluted in the same manner. 
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Statistical Analysis 
Results are expressed as the mean + stand- 
ard error. The standard t test was used to 
analyze the data for significant differences 
between the means. Differences with a P 
value of less than 0.05 were considered 
significant. 
RESULTS 
Evidence of Immunoreactive Gastrin 
Release into Duodenal and Pancreatic 
Juice 
Duodenum. The infusion rate of lactated 
Ringers-phenol red indicator solution into 
the duodenal segment was manipulated dur- 
ing basal and stimulated periods to main- 
tain a minimum effluent volume of 1-2 
ml/min. The average cumulative 30-min 
basal volume (67 k 11 ml) was not sig- 
nificantly different from the volumes col- 
lected at 1, 3, and 5 U/min secretin infusion 
(69 f 11, 59 k 10, and 79 2 10 ml, respec- 
tively; P NS). The cumulative basal re- 
lease of immunoreactive gastrin into duo- 
denal juice was 2225 f 334 pg/30 min. Stim- 
(mean 2 SEM 1 
1 
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FIG. 3. The effects of stepwise increases in secretin 
infusion upon the average cumulative gastrin release 
into the duodenal lumen per 30-min collection period. 
IO 2-J 50 IO P Jo l0 P x) 
minutes 
FIG. 4. The flow response patterns of pancreatic 
juice to increases in secretin dosage. 
ulation with 1 U/min secretin increased this 
value to 3622 + 902 pg. Infusion of 3 U/min 
secretin significantly (P < 0.05) increased 
the secretion to 4949 f 1072 pg, and 5 
U/min secretin infusion caused no further 
increase (4175 + 583 pg). Gastrin release at 
5 U/min secretin infusion was, however, 
significantly (P < 0.02) different from basal 
(Fig. 3). 
Pancreas. Spontaneous flow from the 
pancreatic duct was not observed in the 
basal state. In response to secretin in- 
fusion, the average cumulative flow rose 
from 2.7 + 0.7 ml at 1 U/min of secretin 
to 4.6 t 1.2 ml at 3 U/min and fell to 3.7 
k 0.8 ml at 5 U/min. These values were 
not significantly different. In each instance 
there was a delay lasting about 10 min 
before the secretory response to secretin 
was observed (Fig. 4). Patterns of gastrin 
release were similar to those of juice flow 
(Fig. 5). There was no basal secretion. 
During infusion of 1 U/min secretin the 
average cumulative release of immuno- 
reactive gastrin was 128 2 40 pg. With 
secretin infusion rates of 3 and 5 U/min, 
202 k 48 and 138 k 9.0 pg were released, 
respectively, values which were not sig- 
nificantly different from that with the 1 
U/min infusion. Regression analysis of the 
rate of release of immunoreactive gas&in 
into pancreatic juice (pg/min) versus the 
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FIG. 5. The gastrin release patterns in pancreatic 
juice in response to increases in secretin dosage. 
rate of pancreatic juice flow (ml/min) yielded 
a correlation coefficient of 0.83 (P < O.OOl), 
signifying that the rate of pancreatic gastrin 
release was fow dependent (Fig. 6). 
By extraction, immunoreactive gas&in 
was recovered from tissue samples of duo- 
denum and pancreas. In a limited number 
of experiments, the mean immunoreactive 
gastrin recovered from samples of duodenum 
(N = 3) was 1690 + 235 pg/g and that from 
pancreas (N = 2) was 706 + 214 pg/g. 
Evidence for Immunoreactive Gastrin 
Release into the Portal Vein in Response 
to Secretin Infusion 
By calculation of dialysate gastrin losses, 
there was an average of 7.8% total gastrin 
in the system lost per 30-min collection 
period. This necessitated correction of each 
portal vein gastrin concentration by a factor 
of 0.03%. The average basal gastrin con- 
centration was 49.8 4 4.8 pg/ml. In response 
to 1, 3, and 5 U/min secretin infusion, 
these values rose to 52.7 2 3.5, 65.7 k 2.9, 
and 77.1 k 3.2 pg/ml (Fig. 7). The average 
gas&in concentrations at 3 and 5 U/min 
secretin infusion were significantly (P < 0.01) 
different from basal and the values with 
the infusion of 1 U/min. In addition, the 
gastrin values at all secretin infusion rates 
were significantly (P < 0.01) different from 
each other. Because gastrin accumulated 
in a closed system without active removal, 
portal vein values alone reflect neither the 
total mass secreted nor changes due to 
increasing secretin doses. Hence, the aver- 
age net increment in portal vein immuno- 
reactive gas&in content over and above the 
preceding level was calculated. The incre- 
mental changes in portal venous gastrin 
release are compared with those measured 
in duodenal and pancreatic juice, and are 
depicted in Table I. Similar release patterns 
over time were observed in all six ex- 
periments. 
Isolation and Characterization of 
Immunoreactive Gastrin Released from 
Different Tissues 
When pancreatic juice containing 540 pg 
of immunoreactive gastrin was applied to an 
affinity column containing an antiserum 
covaIently bound to Sepharose, 44% of 
that gastrin was bound and eluted with 
0.1 A4 acetic acid. On rechromatography of 
this material, 100% was bound. Fifty-six 
percent of the gastrin in duodenal juice 
was bound by the column. The column 
capacity was estimated to be 250 pg and 
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FIG. 6. Regression curve of the rate of pancreatic 
juice flow versus the rate of gastrin release into pan- 
creatic juice. 
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FIG. 7. The effect of secretin infusion upon the 
average portal vein immunoreactive gastrin concen- 
trations. 
load of the capacity of the column to bind 
gastrin (Fig. 8). 
Immunoreactive gastrin in both pancreatic 
and duodenal juice was detected using a C- 
terminal reacting antiserum and duodenal 
juice eluted on Sephadex G-50 columns 
as a peptide equivalent in molecular weight 
to CCK.* This peptide did not react with a 
NH,-directed gastrin antiserum, suggesting 
that it contained the C-terminal portion of 
gastrin or CCK.* Rechromatography of 
the gastrin in pancreatic juice obtained by 
acetic acid elution of that bound to the 
affinity column resulted in a single peak 
again equivalent in molecular weight to 
CCKs (Fig. 9). 
Portal vein IG eluted on Sephadex G-50 
predominantly as G34, with a lesser fraction 
corresponding to G17 and smaller peptides 
(Fig. 10). 
DISCUSSION 
The use of an ex viva pancreaticoduo- 
denal perfusion system facilitates study of 
the mechanism(s) of circulatory and luminal 
immunoreactive gastrin (IG) release from 
extra-antral tissues, and avoids many of the 
problems of in viva systems. The place- 
ment of separate collection cannulae into 
the duodenal and pancreatic duct lumens 
allows observation of the dynamics of 
AVERAGE NET CHANGES IN LUMINAL AND PORTAL 
VENOUS RELEASE OF~MMUNOREACTIVE GASTRIN 
(pg/30 min) 
Portal Pancreatic 
vein Duodenum duct 
1 U/min 870 3622 128” 
secretion (+60/o) (+63%) 
3 U/min 3900 4949 202 
secretion (+25%) (+37%) (+58%) 
5 U/min 3420 4175 138 
secretion (-17%) (- 16%) (-32%) 
D No basal output recorded. 
gastrin release from each endocrine organ 
in response to the administration of exoge- 
nous secretin. 
The gastrin concentration in the dog 
duodenal mucosa was approximately 0.0017 
pg/g mucosa, a value somewhat lower than 
that observed by Watson et al. [33]. 
Similar values of duodenal gastrin content, 
however, have been observed by Nilsson 
I 
O.OZM Tris-HCI pH 8.0 1 ‘1”Acetic Acid pH 2.5 
Peak I 
I 




of Peak II of Pancreatic 
Juice (88 pg applied I 
4Or A 
ELUTION VOLUME i ml I 
FIG. 8. The results of affinity chromatography of 
immunoreactive gastrin recovered from pancreatic 
and duodenal juice. 
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FIG. 9. Sephadex GSO superfine chromatography of 
immunoreactive gastrin in canine duodenal and pan- 
creatic juice. 
et al. and Uvnls-Wallensten [22, 291. 
Gastrin content in the dog pancreas was 
approximately 0.0008 &g tissue, 50% 
lower than that in duodenal tissue. 
Immunoreactive gastrin was recovered in 
duodenal juice during basal and secretin- 
stimulated periods. The lack of spontaneous 
juice flow (basal state) from the pancreatic 
duct precludes any comparative statements, 
but gastrin immunoreactivity was present 
in samples collected during secretin-stim- 
ulated periods. The elution patterns on gel 
filtration of pancreatic and duodenal juice 
samples indicated an immunoreactive gas- 
u-in-like peptide smaller than Rehfeld’s 
component IV (G-14 or minigastrin [23, 
241 and nearly equivalent in molecular size 
to CCK.* Uvnas-Wallensten et al. sim- 
ilarly observed gastrin release into the 
duodenal lumen of cats [29], but the 
peptide was not further characterized. 
The concept of hormone release into the 
gut lumen has been viewed with skepticism, 
but several investigators have demonstrated 
gastrin-like peptides in gastric juice of 
man, dog, and cat 11, 8, 13-15, 30, 321. 
In the cat, gastrin from gastric juice has 
been characterized by gel filtration as mainly 
G-17. The recovery from dog duodenal 
and pancreatic juice of a smaller gastrin- 
like peptide containing approximately eight 
of the carboxy-terminal amino acids of 
gastrin or CCK has not been reported. It 
is not surprising that gastrin-like peptides 
are recoverable from pancreatic juice. Lom- 
CCKB Nd*q 64 
TT T 
Blue 
Swhadex G50 C&m I 
Tris Buffer pH 8.0 
40- Flow Rote 4mVh LOlld 







25 50 75 
% Elution (Blue Dextran and Na1251) 
100 
FIG. 10. Sephadex G50 superfine chromatography of immunoreactive gas&in in canine portal 
vein plasma. 
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sky et al. [21] demonstrated in the human 
pancreas cells with gastrin-like immuno- 
reactivity. This observation, however, has 
been disputed by others [3, 171. True 
gastrin cells have been shown to occur in 
the pancreas and duodenum prenatally in 
human [17] and rat [18] species, but 
rarely are identifiable for longer than 2-3 
weeks following birth. In addition, gastrin- 
like immunoreactivity to specific C terminal- 
reacting gastrin antisera, although present 
in gastrinomas and prenatal pancreas, has 
not been demonstrated in adult pancreas 
[ 171. These dissimilar observations, how- 
ever, may be related to fixation problems, 
as pancreatic gastrin-producing D or A, cells 
have histological and histochemical prop- 
erties which differ from those of anti-al 
gastrin-producing G cells and gastrinoma 
cells. 
The administration of secretin to dogs 
and patients with “usual” forms of duodenal 
ulcer disease results in a fall or no change 
in fasting levels of circulating immuno- 
reactive gastrin [28]. Circulating gastrin 
peptides in fasting man and dog have 
been characterized mainly as component II 
(G34) along with minute quantities of 
component IV (G-14) [4, 5, 22, 24, 321. 
The infusion of 1, 3, and 5 U/min Boots 
secretin in our ex viva preparation resulted 
in prompt increases in immunoreactive 
gastrin release into duodenal and pan- 
creatic juice and, to a lesser degree, into 
portal venous blood as well. The quan- 
tities of gastrin released into duodenal juice 
were at least equal to, if not greater than, 
those released into portal venous blood 
(Table 1). The lesser rise in gastrin re- 
lease at 5 U/min secretin into gut and 
pancreatic lumens as well as into portal 
venous blood suggests either a fatigue 
phenomenon or inhibition at the higher 
dose. In all experiments a lo- to 15- 
min lag period preceded the spike increase 
in luminal gastrin release at each secretin 
infusion rate. A similar lag period pre- 
ceding the fall in circulating gastrin levels 
in humans following secretin infusion has 
been observed by Korman ef al. [ 161. 
The increased levels of portal vein gastrin 
observed in the present study cannot be 
attributed solely to pH changes of the 
duodenal pet&sate. Becker et al. [2] 
observed increases in regional venous gas- 
trin release in response to perfusing the 
proximal duodenum of dogs with neutral 
or alkaline saline solutions. The constant 
acid orange color of duodenal effluent 
in all of the present experiments with 
dye indicator suggests that duodenal juice 
alkalinity was not a contributing factor. 
The reason that others have not found 
that secretin is a stimulant for gastrin 
release may be due to measurements taken 
in the whole animal. Thompson et al. 
have shown that endogenous gastrin under- 
goes rapid extraction and degradation (35- 
37% per transit) in the small bowel of 
the dog [27]. Previous experiments (see 
Materials and Methods) showed that less 
than 8% of the immunoreactive gastrin in 
the total system is lost through dialysis 
per 30-min collection period, a cumulative 
loss of less than 25% for the entire study 
period. The lack in our system of an ef- 
ficient mechanism for extraction and deg- 
radation of circulating gas&in may serve 
to explain the rise in portal vein gastrin 
levels following the infusion of secretin. 
The concept of bidirectional release of 
hormone peptides into the gut lumen and 
regional venous circulation is not new. 
Fiddian-Green, Knight, and Vinik have dem- 
onstrated luminal gastrin release in man 
[8, 15, 321, and Uvnas-Wallensten et 
al. described bidirectional immunoreactive 
gastrin release from the antrum of anes- 
thetized cats following vagal stimulation 
[30]. Solcia and colleagues have dem- 
onstrated two types of endocrine cells in 
gastric mucosa: Closed-type cells are limited 
to the gastric corpus and lack direct 
luminal communications; open-type cells, 
on the other hand, are found in the antrum 
and possess microvilli which project into 
the gastric lumen [26]. Ultrastructural 
studies of open-type cells indicates that 
their organization is appropriate not only 
for bidirectional hormone release but also 
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for response to luminally active stimuli, 
including other hormones [ 191. 
Our findings suggest further that bidi- 
rectional gastrin release may occur from 
extra-antral tissues. In the dog, secretin 
stimulation inhibits luminal release of antral 
gas&in and stimulates release from duo- 
denum and pancreas in excess of that into 
portal venous blood. This phenomenon may 
also occur in the human but must be con- 
firmed with further investigation. Ultra- 
structural studies of gastrinomas from pa- 
tients with Zollinger-Ellison syndrome have 
shown the presence of nonuniform-appear- 
ing secretory cells which contain granules 
typical of antral G cells [3]. In addi- 
tion, ductular structures have been fre- 
quently observed in histologic sections of 
gastrinomas [3]. 
Gastrinoma cells are immunohistochem- 
ically similar to antral G cells and react 
equivalently with carboxy terminal-directed 
gastric antisera [17]. The responses of 
gastrinoma cells and antral G cells to exoge- 
nous secretin, however, appear to differ 
markedly, suggesting that the two cell 
types are qualitatively dissimilar. However, 
following the administration of secretin in 
the dog, immunoreactive gastrin is released 
bidirectionally into pancreatic and duodenal 
juice as well as into portal venous blood. 
This observation implies that gastrin-pro- 
ducing G or D cells in the dog are func- 
tionally similar to the “open-type” gastric 
mucosal endocrine cells described by Sol- 
cias. If a similar pattern of gastrin release 
occurs in normal human subjects follow- 
ing secretin stimulation, one might an- 
ticipate negligible changes in circulating 
levels of gastrin because most of the gastrin 
appears in the intestinal lumen. Gastrinoma 
cells, on the other hand, may be mor- 
phologically distinct from normal gastrin- 
producing cells; they may be mainly “closed- 
type” cells with no communications with 
ductal structures. Secretin stimulation might 
then evoke apparent unidirectional release 
directly into portal venous blood. The var- 
iability in the magnitude but not the direc- 
tion of gastrin responses to secretin in 
patients with Zollinger-Ellison syndrome 
may simply reflect differences in tumor size 
and “functional” gastrinoma cell mass. 
SUMMARY 
(1) Small peptides of: eight or nine amino 
acids with gastrin-like immunoreactivity are 
found in duodenal and pancreatic juice in 
the dog. 
(2) These peptides are released into the 
portal circulation in both basal and secretin- 
stimulated states. 
(3) Following secretin infusion in the dog, 
luminal gastrin release from extra-antral 
sites usually exceeds release into the portal 
circulation. 
SPECULATION 
(1) Gastrinoma cells and normal gastrin- 
producing cells may be morphologically 
distinct (closed versus open cell types) 
and differ in their communication with 
ductal structures. 
(2) Hence, the administration of exoge- 
nous secretin to patients with gastrinomas 
(Zollinger-Ellison syndrome) may result 
in a unidirectional release of immuno- 
reactive gastrin into the portal circulation, 
the magnitude of which depends on the 
mass of endocrinologically active tumor. 
(3) These observations may serve to ex- 
plain the paradoxical gastrin response to 
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